Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    No significant content changes detected between the screenshots; the page content remains the same aside from minor UI updates. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T01:23:57.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    42 days ago
    Change Detected
    Summary
    Key updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.
    Difference
    4%
    Check dated 2025-10-05T10:29:48.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-28T03:23:39.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Updated the page to Revision v3.0.2, replacing v3.0.1. The 'Back to Top' element was removed.
    Difference
    0.2%
    Check dated 2025-09-13T17:42:42.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-06T15:26:35.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new facility and location information, as well as detailed medical content related to neoplastic processes and the drug pembrolizumab. The previous version's references to certain locations and specific antineoplastic agents have been removed.
    Difference
    3%
    Check dated 2025-08-30T12:13:36.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.